Carilion Rockbridge Community Hospital
Carilion Rockbridge Community Hospital was paid $11.82M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
LEXINGTON, VA 24450
Next to other Multi-Specialty Clinic/Center providers in Virginia
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,189 | $420K | |
| 2019 | 19,551 | $990K | |
| 2020 | 23,517 | $1.43M | |
| 2021 | 29,853 | $1.82M | |
| 2022 | 33,767 | $2.20M | |
| 2023 | 38,924 | $2.67M | |
| 2024incomplete | 27,304 | $2.29M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 10,117 | 8,934 | $2.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 10,994 | 9,234 | $2.22M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 3,360 | 2,955 | $1.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 5,185 | 4,459 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 3,018 | 2,781 | $651K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 6,960 | 2,179 | $559K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,005 | 1,708 | $557K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 1,764 | 1,464 | $454K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 2,992 | 2,753 | $288K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 453 | 432 | $243K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 887 | 815 | $191K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,399 | 1,216 | $153K |
113 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 448 | $148K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 787 | $110K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,472 | $102K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 411 | $101K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 804 | $69K |
| 97161 | <1% | 352 | $66K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 172 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,714 | $52K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 398 | $44K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 588 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 6,993 | $42K |
| 97162 | <1% | 118 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,229 | $30K |
| 99220 | <1% | 363 | $24K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 427 | $23K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,562 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,910 | $18K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,131 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 369 | $12K |
| 74018 | <1% | 231 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,109 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,943 | $9K |
| 72100 | <1% | 159 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 100 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $8K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 829 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 43 | $6K |
| 83880 | <1% | 663 | $6K | |
| 93017 | <1% | 39 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 47 | $6K |
| 97014 | <1% | 93 | $5K | |
| 84484 | <1% | 3,948 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,166 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,850 | $4K |
| 73630 | <1% | 268 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 154 | $4K |
| 73610 | <1% | 213 | $3K | |
| 73030 | <1% | 124 | $3K | |
| 73562 | <1% | 106 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 31 | $3K |
| 85379 | <1% | 465 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 18 | $2K |
| 81025 | <1% | 2,476 | $2K | |
| 83690 | <1% | 2,985 | $2K | |
| J3490 | Unclassified drugs | <1% | 9,270 | $2K |
| 83605 | <1% | 1,791 | $1K | |
| 81001 | <1% | 4,847 | $1K | |
| 80076 | <1% | 576 | $987.12 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,288 | $837.21 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 35 | $828.46 |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,273 | $808.37 |
| 83735 | <1% | 3,304 | $768.47 | |
| 73130 | <1% | 70 | $764.29 | |
| 82962 | <1% | 1,720 | $684.69 | |
| 99235 | <1% | 46 | $674.82 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 12 | $647.77 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,671 | $604.25 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,415 | $588.71 |
| 80306 | <1% | 322 | $576.63 | |
| 81003 | <1% | 1,354 | $480.48 | |
| 84703 | <1% | 1,366 | $469.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 499 | $437.89 |
| 85027 | <1% | 183 | $409.31 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,114 | $374.69 |
| G0378 | Hospital observation service, per hour | <1% | 19 | $370.21 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,813 | $346.92 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,287 | $340.47 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 909 | $287.88 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,707 | $238.72 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $228.77 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,388 | $225.41 |
| 87040 | <1% | 177 | $209.70 | |
| 96376 | <1% | 801 | $185.84 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $176.43 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,514 | $161.90 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,309 | $139.48 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 44 | $125.30 |
| 87081 | <1% | 732 | $109.35 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,573 | $109.05 |
| 73110 | <1% | 15 | $99.13 | |
| 80047 | <1% | 15 | $96.14 | |
| 86140 | <1% | 28 | $83.40 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $51.17 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 562 | $48.24 |
| 85610 | <1% | 241 | $42.16 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,845 | $36.02 |
| 87186 | <1% | 144 | $32.42 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 440 | $31.06 |
| 85652 | <1% | 58 | $28.95 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $19.44 |
| 85014 | <1% | 16 | $11.57 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 301 | $11.25 |
| 82803 | <1% | 16 | $9.27 | |
| 86850 | <1% | 32 | $7.16 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 190 | $5.01 |
| 86900 | <1% | 34 | $3.58 | |
| 86901 | <1% | 36 | $3.58 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 54 | $3.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 57 | $1.80 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 521 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 51 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 17 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 17 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| 84702 | 0% | 16 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 17 | $0.00 |
| 87077 | 0% | 27 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 46 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 43 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 206 | $0.00 |
| 85730 | 0% | 31 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.